3:42 PM
Feb 01, 2019
 |  BioCentury  |  Finance

Shanghai’s New Chapter

How a new Shanghai exchange board could compete for biotech listings

A planned science and technology innovation board on the Shanghai Stock Exchange could provide another route to public funding for Chinese life science companies within a matter of months. While the exchange may not compete with the Hong Kong stock exchange and NASDAQ for global biotech listings anytime soon, it may be a destination for companies that have not been able to access those markets.

The proposed board was first announced by Chinese President Xi Jinping in November and approved by China's government on Jan. 23. As a priority of the China Securities Regulatory Commission, the board is likely to get off the ground quickly.

Draft guidelines released on Jan. 29 indicate preprofit companies with at least one innovative therapy approved to enter Phase II testing would be eligible to list on the...

Read the full 647 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >